WBL Medical Group (hereinafter referred to as "WBL"), with its breakthrough achievements in Low-Intensity Pulsed Ultrasound (LIPUS) treatment for erectile dysfunction (ED), has successfully been featured on CCTV's "Science and Innovation China" program. This achievement is the result of the outstanding contributions and years of relentless efforts by China's renowned urology expert, Professor Xin Zhongcheng.
WBL Featured on CCTV's "Science and Innovation China"
WBL became the focus of CCTV's "Science and Innovation China" program with its self-developed LIPUS-ED treatment device. This device uses low-intensity pulsed ultrasound technology for the successful treatment of erectile dysfunction, filling a gap in this field both domestically and internationally. The WBL LIPUS-ED device has not only won the China National Medical Device Innovation Award but also received approval from the China Food and Drug Administration (CFDA) in 2018, becoming the world’s first LIPUS device approved for ED treatment.
Expert Introduction
Professor Xin Zhongcheng, M.D.
Chief Physician, Department of Urology, Peking University First Hospital
Professor, Ph.D. Supervisor
Chief Expert of Urology at Tianjin Medical University Second Hospital
Director of the Male Reproductive and Sexual Medicine Laboratory, Tianjin Urology Research Institute
Executive Director of the Chinese Medical Promotion Association
Chairman of the Male Reproductive and Sexual Medicine Subcommittee, Chinese Medical Promotion Association
Advisory Expert for the International Society for Sexual Medicine (ISSM/ICSM)
Past President of the Asia-Pacific Society for Sexual Medicine (APSSM)
Executive Editor of the Journal of Translational Urology and Andrology (TAU)
Director of the Beijing Zhongke Jingfu International Institute of Andrology (BZIAA)
Professor Xin Zhongcheng is an authoritative expert in Chinese urology and male reproductive medicine, dedicated to clinical and basic research on erectile dysfunction, male infertility, and related diseases. Professor Xin has made groundbreaking progress in the development of LIPUS-ED and has published numerous high-level papers in the field of male reproductive medicine. He has also edited several authoritative textbooks, including "Textbook of Male Reproductive Medicine" and "Textbook of Surgical Treatment for Erectile Dysfunction." His research achievements have not only advanced the development of male health in China but also brought new hope for ED patients worldwide.
The success of WBL's LIPUS-ED development could not have been achieved without the support and collaboration of experts both domestically and internationally. Professor Xin Zhongcheng and his team at Peking University First Hospital's Molecular Biology Laboratory, Male Urology Center, conducted safety and efficacy studies using a diabetic rat ED model. The results showed that the ultrasound therapy device effectively and safely improved erectile function in diabetic ED rats. The mechanism of action involves the repair of pathological changes in the penis, including repairing endothelial cell damage in the corpus cavernosum, nerve damage, and fibrosis. This mechanism is likely related to the ability of LIPUS to promote the expression of VEGF, eNOS, and nNOS proteins, inhibit the TGF-β1/Smad/CTGF signaling pathway, enhance the NO-GMP signaling pathway, and regulate the activity of endogenous stem cells. Professor Xin Zhongcheng and his team played a crucial role in the transition from experimental results to the development of the device. During the production of the WBL LIPUS device, they optimized the frequency, intensity, and emission modes of the ultrasound.
To investigate the efficacy and safety of WBL’s LIPUS in the clinical treatment of ED patients, a multi-center, randomized, double-blind, placebo-controlled clinical study was conducted in 2015. Led by Professor Xin Zhongcheng, the study was a collaboration between Peking University First Hospital, Weifang Medical College Affiliated Hospital, Lanzhou University Second Hospital, Zhengzhou University First Affiliated Hospital, and Beijing Chaoyang Hospital, Capital Medical University. The study aimed to validate the efficacy and safety of low-intensity pulsed ultrasound (LIPUS) in treating mild to moderate ED. The findings were published in the "Original Article" journal. The clinical trial results showed that the low-intensity pulsed ultrasound therapy device developed by Beijing WBL Medical Device Co., Ltd. effectively treats erectile dysfunction, with a safe and effective clinical outcome. The mechanism of action is related to the non-invasive mechanical stimulation of low-intensity pulsed ultrasound, which adjusts tissue cell biological effects through mechanical-biological transmission, including the regulation of endogenous stem cells, thereby repairing pathological changes in the penis, such as repairing endothelial cell damage, nerve damage, and fibrosis in the corpus cavernosum. This ultimately restores erectile function and further promotes the application of WBL's LIPUS technology in regenerative medicine and clinical practice.
WBL’s feature on CCTV's "Science and Innovation China" program is also a breakthrough for ED patients worldwide. In the future, with the application of LIPUS technology in more disease fields, LIPUS research will continue to lead the development of regenerative medicine, making greater contributions to human health.